eCommons@AKU
Woman and Child Health

Division of Woman and Child Health

August 2011

Vitamin A supplements for preventing mortality,
illness, and blindness in children aged under 5:
systematic review and meta-analysis
Evan Mayo-Wilson
Aamer Imdad
Aga Khan University

Kurt Herzer
Mohammad Yawar Yakoob
Aga Khan University

Zulfiqar Ahmed Bhutta
Aga Khan University, zulfiqar.bhutta@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_wc
Part of the Pediatrics Commons
Recommended Citation
Mayo-Wilson, E., Imdad, A., Herzer, K., Yakoob, M., Bhutta, Z. A. (2011). Vitamin A supplements for preventing mortality, illness,
and blindness in children aged under 5: systematic review and meta-analysis. British Medical Journal, 343, D5094.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/87

BMJ 2011;343:d5094 doi: 10.1136/bmj.d5094

Page 1 of 19

Research

RESEARCH
Vitamin A supplements for preventing mortality, illness,
and blindness in children aged under 5: systematic
review and meta-analysis
OPEN ACCESS

Evan Mayo-Wilson departmental lecturer 1, Aamer Imdad senior research officer 2, Kurt Herzer
Marshall scholar 1, Mohammad Yawar Yakoob senior research officer 2, Zulfiqar A Bhutta Noordin
Noormahomed Sheriff endowed professor and founding chair 2
1

Centre for Evidence-Based Intervention, Department of Social Policy and Intervention, University of Oxford, Barnett House, Oxford OX1 2ER, UK;

2

Division of Women and Child Health, Aga Khan University Hospital, Stadium Road, PO Box 3500, 74800 Karachi, Pakistan

Abstract
Objective To determine if vitamin A supplementation is associated with
reductions in mortality and morbidity in children aged 6 months to 5
years.
Design Systematic review and meta-analysis. Two reviewers
independently assessed studies for inclusion. Data were double
extracted; discrepancies were resolved by discussion. Meta-analyses
were performed for mortality, illness, vision, and side effects.
Data sources Cochrane Central Register of Controlled Trials (CENTRAL)
in the Cochrane Library, Medline, Embase, Global Health, Latin American
and Caribbean Health Sciences, metaRegister of Controlled Trials, and
African Index Medicus. Databases were searched to April 2010 without
restriction by language or publication status.
Eligibility criteria for selecting studies Randomised trials of synthetic
oral vitamin A supplements in children aged 6 months to 5 years. Studies
of children with current illness (such as diarrhoea, measles, and HIV),
studies of children in hospital, and studies of food fortification or β
carotene were excluded.
Results 43 trials with about 215 633 children were included. Seventeen
trials including 194 483 participants reported a 24% reduction in all cause
mortality (rate ratio=0.76, 95% confidence interval 0.69 to 0.83). Seven
trials reported a 28% reduction in mortality associated with diarrhoea
(0.72, 0.57 to 0.91). Vitamin A supplementation was associated with a
reduced incidence of diarrhoea (0.85, 0.82 to 0.87) and measles (0.50,
0.37 to 0.67) and a reduced prevalence of vision problems, including
night blindness (0.32, 0.21 to 0.50) and xerophthalmia (0.31, 0.22 to
0.45). Three trials reported an increased risk of vomiting within the first
48 hours of supplementation (2.75, 1.81 to 4.19).

Conclusions Vitamin A supplementation is associated with large
reductions in mortality, morbidity, and vision problems in a range of
settings, and these results cannot be explained by bias. Further placebo
controlled trials of vitamin A supplementation in children between 6 and
59 months of age are not required. However, there is a need for further
studies comparing different doses and delivery mechanisms (for example,
fortification). Until other sources are available, vitamin A supplements
should be given to all children at risk of deficiency, particularly in low
and middle income countries.

Introduction
Vitamin A refers to a subclass of retinoic acids1 long understood
to help regulate immune function and to reduce morbidity of
infectious diseases.2 Vitamin A is required for normal
functioning of the visual system, maintenance of cell function
for growth, epithelial integrity, production of red blood cells,
immunity, and reproduction.3 Different forms of vitamin A
include β carotene, which is found in plants, and preformed
vitamin A, which is found in animal sources. Vitamin A is an
essential nutrient that cannot be synthesised so it must be
obtained through diet.1
Vitamin A deficiency increases vulnerability to a range of
illnesses including diarrhoea, measles, and respiratory
infections.3 4 These are leading causes of mortality among
children in low and middle income countries,5 where risk of
infection and risk of mortality can be compounded by coexisting
undernutrition.6 The bioavailability of provitamin A carotenoids
in fruit and vegetables is lower than once believed,7 8 and it is
difficult for children to fulfil their daily requirements through
plant foods alone. Consequently, vitamin A deficiency is
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common among children whose families cannot afford eggs and
dairy products.

Preformed vitamin A (retinol, retinal, retinoic acid, and retinyl
esters) is the most active in humans; it is usually used in
supplements in the form of retinyl esters.1 3 High intake of
synthetic vitamin A over a prolonged period can lead to toxicity,9
but toxicity from food sources is rare. Periodic supplementation
should not cause serious adverse effects.10
Previous meta-analyses suggested that vitamin A
supplementation for children in developing countries is
associated with up to 30% reductions in mortality,11-13 especially
deaths from diarrhoea and measles. The World Health
Organization has long recommended vitamin A supplementation
for children aged under 5 and for pregnant and breastfeeding
mothers.14 The Countdown to 2015 identified 68 “priority
countries” in which over 90% of the world’s maternal and
childhood deaths occur15; the programme aims to hold
governments accountable for their commitments to Millennium
Development Goals. Vitamin A is now being provided in many
low and middle income countries with coverage rates of 86%.15
Nonetheless, some critics have questioned the value and
effectiveness of vitamin A supplementation programmes, and
several studies have been conducted since initial
recommendations were made.16 17

We undertook a review to synthesise all available evidence for
vitamin A supplementation in children aged 6 months to 5 years,
adding to previous reviews by investigating effects on mortality
and the illnesses that lead to death. By investigating all effects
in the same review, we provided current estimates of treatment
effects and identified potential pathways through which vitamin
A supplementation might reduce mortality. A complete protocol
was peer reviewed and published by the Cochrane Collaboration,
and the review is available in the Cochrane Library.18

Methods
We evaluated the effect of prophylactic synthetic oral vitamin
A supplementation compared with no treatment or placebo. We
planned to conduct five subgroup analyses:
• Dose: WHO recommended dose (up to 100 000 IU for
children aged 6-11 months and 200 000 IU for children
aged 1-5 years) v lower and higher doses
• Frequency: high (doses within 6 months) v low (1 dose or
≥6 month interval)
• Location: by continent

• Age: 6-12 months v 1-5 years
• Sex: boys v girls.

Eligibility criteria
Types of trials—Randomised controlled trials including cluster
trials and factorial trials were included irrespective of publication
status or language.
Types of participants—At the time of recruitment, children had
to be aged 6 months to 5 years and apparently healthy. Children
in hospital at the time of recruitment were excluded.
Types of interventions—Included studies examined synthetic
oral vitamin A supplementation compared with no treatment or
placebo, irrespective of dose or frequency. Studies of food
fortification and β carotene supplementation were excluded as
their effects can differ.

No commercial reuse: See rights and reprints http://www.bmj.com/permissions

Types of outcome measures
Primary—We examined all cause mortality at the longest
follow-up. We also analysed outcomes within the first year and
more than one year after supplementation.

Secondary—We analysed cause specific mortality from
diarrhoea, lower respiratory tract infection, measles, and
meningitis. We compared the incidence and prevalence of
diarrhoea, lower respiratory tract infection, measles, malaria,
meningitis, Bitot’s spots, night blindness, and xerophthalmia.
Adverse events were noted and analysed when possible
(vomiting and bulging fontanelle). Finally, we examined vitamin
A status (serum retinol) as a continuous and dichotomous
outcome.

Search strategy
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL 2010, issue 2), Medline (see box), Embase, Global
Health, Latin American Database (LILACS), metaRegister of
Controlled Trials, and African Index Medicus (see appendix 1
on bmj.com). All searches were conducted on 27 April 2010.
To identify ongoing and unpublished trials, we used the WHO
international clinical trials registry, which searches multiple
trial registries. Reference lists of reviews, included studies, and
excluded studies were searched for additional citations. We
contacted organisations and researchers by email and by phone.
Two authors (from AI, KH, and MYY) independently screened
abstracts and resolved differences with a third author (EMW).

Assessment of bias
Studies were assessed with the Cochrane Collaboration’s risk
of bias tool.19 Two authors rated each study for risk of bias from
sequence generation (was the method truly random?), allocation
concealment (before enrolment, were participants’ group
assignments disguised?), blinding of participants, assessors, and
providers (was assignment adequately disguised after
randomisation?), selective outcome reporting (were all outcome
measures reported?), and incomplete data (do the results account
for all participants randomised?). Risk of bias for each domain
was rated as high (seriously weakens confidence in the results),
low (unlikely to seriously alter the results), or unclear.
Discrepancies were resolved through discussion. The primary
analysis was repeated without studies at high risk of bias for
sequence generation.

Data management
Two independent people, at least one of whom was an author,
completed data extraction and assessments of risk of bias online
with Distiller software.20 We collected data on the time points
and measures (both collected and reported) and recruitment,
inclusion/exclusion criteria, co-interventions, dose, frequency,
duration, age, sex, setting, and location.

Statistical analysis
For continuous outcomes, we calculated the standardised mean
difference, Hedges’ g.21 For dichotomous outcomes, we
calculated an overall risk ratio. For incidence data, risk ratio
(events per child) and rate ratio (events per child year) were
combined because these ratios use the same scale and can be
interpreted in the same way for these studies (the duration of
studies was short and there was no interaction between the
intervention and time at risk). All outcomes are reported with
95% confidence intervals, and overall effects are weighted by
the inverse of variance with a fixed effect model. In the case of
Subscribe: http://www.bmj.com/subscribe
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Search strategy for Medline
Medline (1950 to April (week 2) 2010)
1. exp infant/ or exp child/ or exp child, preschool/
2. (baby or babies or infant$ or toddler$ or child$ or girl$ or boy$ or pre school$ or pre-school$ or preschool$).tw.
3. 1 or 2
4. exp Vitamin A/
5. (retinol$ or retinal$ or aquasol a or vitamin a).ab,ti.
6. 4 or 5
7. randomised controlled trial.pt.
8. controlled clinical trial.pt.
9. randomized.ab.
10. placebo.ab.
11. drug therapy.fs.
12. randomly.ab.
13. trial.ab.
14. groups.ab.
15. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. exp animals/ not humans.sh.
17. 15 not 16
18. 3 and 6 and 17

cluster randomised controlled trials, we used adjusted estimates
reported by the authors. Where results did not control for
clustering, we contacted authors to request the intracluster
correlation coefficient. If authors were unable to provide this,
we used design effects calculated previously11 to calculate it
using Cochrane methods.19 For estimated values, we conducted
sensitivity analyses using larger and smaller design effects to
determine if the results were robust.

Eight trials nearly met the inclusion criteria but were excluded
because they were not randomised controlled trials,70-73 were
designed to treat diarrhoea74 or Bitot’s spots,75 focused on
children with HIV, 76 or did not include an eligible comparison.77

Statistical heterogeneity was assessed by visual inspection of
forest plots, by performing χ2 tests (assessing the P value), and
by calculating the I2 statistic,22 23 which describes the percentage
of observed heterogeneity that would not be expected by chance.
If the P value was less than 0.10 and I2 exceeded 50%, we
considered heterogeneity to be substantial. In subgroup analyses,
we tested differences between groups with χ2. To assess the
possibility of small study bias, we compared random effects
estimates with fixed effects estimates, drew funnel plots for
outcomes with 10 or more studies, and conducted a trim and
fill analysis,24 which yields an effect adjusted for funnel plot
asymmetry. Meta-analysis was conducted with RevMan25 and
Biostat CMA (comprehensive meta-analysis)26 and a summary
of results was prepared with the GRADE system.27

Study characteristics

Missing data were noted for each outcome. When the numbers
of dropouts were not reported, we contacted the authors. When
analyses were reported for completers as well as controlled for
dropouts (for example, imputed with regression methods), we
used the latter.

Results

Trial flow
We included 43 trials28-69 reported in 90 papers; 39 (90%)
reported data that could be included in a meta-analysis (fig 1⇓).
The others reported outcomes that were not relevant to the
review35 and data that were not available by group43 or were
incomplete.62 66 Post hoc, we included two studies in which
participants were assigned using quasi-random methods
(alternating assignment) as described below.41 65
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

Two trials could not be assessed at this time. One including 36
children could not be located and is unlikely to affect the
results.78 One completed trial, the deworming and vitamin A
(DEVTA) trial, seems likely to meet the eligibility criteria and
could be included in further updates of this review.79 To assess
how the results of that trial could affect the conclusions of our
review, we conducted a sensitivity analysis for the primary
outcome.

Trials included 215 633 participants with a median sample size
of 480, ranging from 3566 to over 29 000.63 The 39 trials that
were analysed included 215 043 participants (99.8% of children
included in the review).
Of the 43 included trials, 37 compared vitamin A
supplementation with placebo. Four used factorial designs,
combining vitamin A supplementation with other treatments
such as zinc46 51 62 or deworming.55 In one trial,51 raw data were
not available and we could not identify outcome data for an
eligible comparison. Different doses were combined for the
main analysis in one trial.40

The median of the mean ages was 30.5 months. Most trials
assigned equal numbers of boys and girls; three studies favoured
boys by more than 10%.45 54 57 When trials reported outcomes
at multiple time points, we analysed the longest follow-up; most
studies lasted about one year. Table 1⇓ describes characteristics
for individual studies, and table 2⇓ shows counts for subgroup
characteristics.

Risk of bias
Figure 2 shows the risk of bias ratings19 for each trial.⇓ Three
trials were at high risk of bias for sequence generation (not truly
random), and these included 41 139 participants.29 41 65 In two
Subscribe: http://www.bmj.com/subscribe
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quasi-random studies (included post hoc), the authors and the
Cochrane editors agreed that the methods of assignment had
the desirable characteristics of randomisation and were at no
greater risk of bias than other included studies. Only one study
was at high risk of bias because of inadequate allocation
concealment, but concealment of the allocation sequence was
not sufficiently described in 27 trials.

Lack of blinding of assessors created a high risk of bias in only
two studies, but it was unclear if assessors were blind in 14
trials. Two studies were at high risk of bias for failing to blind
project staff, and 13 trials were unclear on this issue. At the trial
level, nine were at high risk of bias for missing data and 12 were
unclear, though missing data for the primary outcome was not
a concern.

Only four studies seemed to be completely free from selective
outcome reporting. It was unclear if 24 trials reported all
outcomes, but the primary outcome (mortality) was known for
almost all participants in the review. To test for bias, the primary
analysis was repeated without studies at high risk of bias for
sequence generation.

Quantitative data synthesis
All cause mortality

Mortality (fig 3⇓) was reported in 17 trials including 194 483
children (90% of the children in the review); one reported no
events and was not analysed.45 Thus, 16 trials were included in
the primary meta-analysis. Two studies41 65 randomised
households, and we treated them as if they had randomised
individuals. Previously reported design effects11 were used to
calculate intracluster correlation coefficients for six cluster
randomised studies.37 52 56 63 68 69 The coefficients were consistent,
and we imputed an intracluster correlation coefficient of 0.002
for all studies in which clustering was not considered in the
original analysis. A sensitivity analysis was conducted for all
cause mortality with coefficients of 0 and 0.01 for those studies
in which the mean design effect was estimated.

Vitamin A was associated with a 24% reduction in all cause
mortality (0.76, 95% confidence interval 0.69 to 0.83; fig 3),
though there was moderate heterogeneity (χ2=29.10, df=15,
P=0.02; I2=48%). Only five trials36 38 48 56 68 (7% of trials)
measured mortality after 13 months, and the effect was similar
(0.75, 0.64 to 0.88) with substantial and significant heterogeneity
(χ2=9.29, df=4, P=0.05; I2=57%).
We then added a study awaiting assessment to the analysis.79 In
an analysis of 17 trials, this study (the deworming and vitamin
A trial) accounted for 65.2% of the combined effect (fig 4⇓),
which remained significant (0.88, 0.84 to 0.94) with substantial
and significant heterogeneity (χ2=44.31, df=16, P<0.001;
I2=64%). Though the benefit of vitamin A decreased by half
(24% to 12%), the result remained clinically important. As we
were unable to assess the trial, we cannot explain this
substantially different result; its impacts on the conclusions of
this review are considered below.

Of those in the main analysis, 10 trials were conducted in Asia,
five in Africa, and one in Latin America. There was no clear
difference (P=0.12) between the Asia subgroup (0.69, 0.61 to
0.79) and the Africa subgroup (0.85, 0.73 to 0.98), though the
Latin American trial reported no effect (1.00, 0.14 to 7.08). We
planned to compare trials in urban and rural areas, but only two
urban trials reported the primary outcome; an analysis comparing
1982 and 192 501 participants would be difficult to interpret.

0.57 to 0.82); the subgroups did not differ significantly (P=0.46).
Five trials reported separate effects for boys (0.80, 0.66 to 0.97)
and girls (0.79, 0.65 to 0.95), which were not significantly
different (P=0.89). Notably, effects for sex and age subgroups
are all larger than the overall result, and these results should be
interpreted with caution.

Only one trial providing small frequent doses reported mortality
data, and the effects were larger (0.46, 0.30 to 0.71) than the
effects for the WHO recommended dose delivered every four
to six months (0.81, 0.72 to 0.90) or the recommended dose
delivered once (0.66, 0.52 to 0.83). Differences between
subgroups were significant (P=0.02), but only the greater effect
for small frequent doses seems clinically plausible (fig 5⇓).
Of the trials at high risk of bias from sequence generation, only
one contributed to primary analysis, and it reported no effect
(1.06, 0.82 to 1.37), indicating that these trials were not likely
to inflate the combined effect.

The primary analysis was repeated with a random effects model,
and the overall estimate was slightly larger; thus, heterogeneity
is partially explained by small studies reporting larger effects
(0.71, 0.61 to 0.84), which could be related to bias or to clinical
differences (such as better implementation in small trials). We
drew a funnel plot and conducted a trim and fill analysis (fig
6⇓). There was some evidence of asymmetry (five studies
trimmed), but the overall effect was strongly influenced by five
studies that accounted for over 80% of the weighted mean, and
there was no effect of replacing missing studies (adjusted value
rate ratio=0.80, 0.73 to 0.87).

We also conducted a sensitivity analysis to determine if the
intracluster correlation coefficients used to adjust for clustering
influenced the overall effect. The size of the effect was slightly
smaller when these trials were treated as if they had randomised
individuals (0.81, 0.75 to 0.89) and was unchanged when we
increased the coefficient to 0.01 (0.75, 0.68 to 0.83). Adjusting
three studies for which the intracluster correlation coefficients
was unknown did not affect our conclusions; further inflating
their standard errors would increase the size of the overall effect.

Cause specific mortality

Vitamin A supplementation was associated with a 27% reduction
in deaths from diarrhoea. Differences in deaths from measles
and meningitis were not significant (table 3⇓).

Morbidities

Morbidity was measured in different ways, and we combined
all available data whenever possible. For example, for diarrhoea
we included all types of diarrhoea (mild, moderate, and severe).
Pneumonia and lower respiratory tract infection outcomes were
combined post hoc because pneumonia is a type of lower
respiratory tract infection and many studies did not have
complete diagnostic information.
Overall, there was a 15% decrease in diarrhoea incidence (fig
7⇓) and a 50% decrease in incidence of measles (fig 8⇓);
heterogeneity in the former analysis was substantial, but
heterogeneity in the second was not important. Only one trial
reported incidence of malaria, which showed a reduction, and
effects on lower respiratory infections were not significant (table
3⇓). Few studies reported prevalence data; results for diarrhoea
and malaria were not significant, and there were no data for
measles.

Four trials reported separate effects for children aged 6-12
months (0.59, 0.43 to 0.82) and children aged 1-5 years (0.68,
No commercial reuse: See rights and reprints http://www.bmj.com/permissions
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Vision

Evidence for vision outcomes was based on a small number of
small studies. The available studies suggest a large reduction
in the incidence and prevalence of night blindness and a large
reduction in the prevalence of xerophthalmia, but effects on
Bitot’s spots and the incidence of xerophthalmia were not
significant (table 4⇓).

Vitamin A deficiency

Serum concentrations were measured in a small number of small
studies. These suggest that vitamin A supplementation reduces
the proportion of children who are deficient and increases
vitamin A serum concentrations (table 4⇓), but heterogeneity
was substantial. These results could be influenced by bias, and
serum concentrations might be a poor indicator of vitamin A
status.

Adverse events

Three trials reported that high doses of vitamin A triple the risk
of vomiting within 48 hours. Results for fontanelle side effects
were not significant in one study (table 4), and two studies that
measured the outcome could not be analysed.

Discussion
Comparable with previous reviews, this review shows that
vitamin A supplementation is associated with large and
important reductions in mortality for children in low and middle
income countries. This adds substantively to previous reviews11-13
in providing a plausible pathway and indicating that vitamin A
supplementation reduces the incidence of and mortality from
diarrhoea and measles. Vitamin A also reduces precursors to
blindness. While there was a slight increase in the risk of
vomiting within 48 hours, there was no evidence of serious
adverse events as a result of periodic supplementation. Most
trials did not measure vitamin A serum concentrations at
baseline as children are unlikely to experience serious harm
under these conditions; continuous supplementation, however,
might lead to toxicity and cause more severe side effects. It is
unclear if smaller more frequent doses would lead to the same
minor side effects observed in this review.9
Vitamin A deficiency is common during childhood in many
low and middle income countries, even among populations
whose diets rely heavily on vegetables and fruits.80 The reasons
are multiple and include widespread maternal undernutrition,
poor dietary quality, and losses during diarrhoea.81 82 WHO
estimates that 122 countries have a moderate to severe public
health problem.83

Strengths and limitations
For the primary outcome, the evidence in this review is strong.
Sixteen studies were analysed, which included a large number
of children. Subgroup and sensitivity analyses show that the
result is robust and the effects of bias were not important.

For the primary outcome, the quality of the evidence was “high”
on the GRADE scale27—that is, further trials are unlikely to
change the conclusion that vitamin A supplementation has a
large and significant effect (table 3). It seems unlikely that the
primary outcome is significantly overestimated because of bias
from any source. Almost all studies were randomised with
appropriate methods for sequence generation, and allocation
was well concealed. It was easy to blind participants and
providers, and most trials reported that people were unaware of
the treatments being provided. Furthermore, lack of blinding
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

might underestimate rather than overestimate effects—for
example, a teacher might give extra food to a child receiving a
placebo. Failure to blind assessors is unlikely to influence
mortality data. Risks of selective outcome reporting and
publication bias are low; the primary analysis included nearly
all participants who had been randomised, and all studies large
enough to make a difference in this analysis are probably known.
Two trials at high risk of bias for sequence generation were
included post hoc, but steps to maintain allocation concealment
and blinding minimised the possibility that participants were
treated differently between groups. In the first, participants were
assigned alternately by household.41 The second used a random
starting point and alternating distribution of red or green pills;
the manufacturer held the code until the study was completed.65
The decision to include these studies was made before data were
extracted, and the one study that contributed to the primary
outcome41 reported no effect (1.06, 0.82 to 1.37). The decision
to include these studies did not result in an overestimation of
the primary outcome.
This review makes an important contribution by identifying
several pathways though which vitamin A could reduce
mortality. Much of the reduction in all cause mortality is
probably explained by reductions in death from diarrhoea and
measles, which are leading contributors to child mortality in
low and middle income countries.5 This hypothesis is
strengthened by a review indicating that vitamin A
supplementation prevents acute diarrhoea from becoming
chronic.84 Though the overall effect for mortality from measles
was not significant, the trend was consistent with the overall
results, and the therapeutic effects of vitamin A supplementation
for measles are well established.78
For the secondary outcomes, the quality of the evidence was
variable on the GRADE scale (tables 3 and 4), though evidence
for measles incidence was high quality. We downgraded ratings
for diarrhoea and measles mortality to “moderate” because of
uncertainty about the size of the effects; these results are
consistent with other findings and consistent with biological
mechanisms through which vitamin A supplementation could
cause an overall reduction in mortality.

In general, large studies examined effects on mortality while
small studies measured illness, vision, and vitamin A serum
concentrations. A few studies measured growth, though we did
not include this as an outcome. Different outcomes are
appropriate for studies with different purposes, but many
secondary analyses include only a small proportion of the
participants in the review. Recent evidence suggests that the
prevalence of selective reporting of outcomes is high and that
this might substantially bias systematic reviews.85 86 If outcomes
were reported selectively, addition of unreported data might
influence the observed effects in some secondary analyses; we
have more confidence in the internal validity of the primary
outcome than the secondary outcomes.
Secondary outcomes also have less external validity than the
primary analysis, and differences in the size of included studies
could mask differences in the size of the analyses. For example,
the primary analysis includes 16 trials while analyses for
incidence of diarrhoea and serum concentration include 12 and
13 trials. Only five trials appear in both the primary analysis
and the diarrhoea analysis, and only three appear in both the
primary and serum analyses. While the primary outcome
includes 194 483 participants (90% of those randomised), the
analysis of incidence of diarrhoea includes only 37 710 (17%)
and the serum analysis includes 6623 (that is, less than 3% of
participants in the review). To draw attention to these differences
Subscribe: http://www.bmj.com/subscribe
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in external validity and risk of bias, tables 3 and 4 include the
number of participants in each analysis as a percentage of those
randomised.87

Comparison with earlier reviews
Landmark reviews of vitamin A for children appeared in
1993.11 13 Since then, nine studies contributing 30% of the
children in this review have improved the quality of the evidence
for vitamin A supplementation in children aged under 5 years.

For the primary outcome, we conducted a cumulative
meta-analysis (fig 9⇓) to show how the effect has shifted with
the addition of studies over time. That is, each point on the plot
shows the combined effect of the new study and all studies
reported before it, and the weight is the combined weight of all
studies up to that time. Eight trials were included in a 1993
review,11 which reported a 23% reduction in all cause mortality
(0.77, 0.70 to 0.86). Eight trials were added to this analysis (one
additional trial reported no events), and the overall estimate has
changed by 1%. The overall effect is not meaningfully different
from the result of the first trial published in 1986. Therefore,
this review confirms that previous estimates remain valid,
finding little evidence of secular trends.
Supplementation in other populations is more controversial. A
recent review of vitamin A supplementation for children aged
under 6 months found no overall effect, but differences between
regional subgroups might have been important.88

Comparison with the deworming and vitamin
A (DEVTA) trial
The most important qualification of these findings is that a large
study, awaiting assessment, found no benefit of vitamin A
supplementation. Some reviews have found only fair agreement
between the results of meta-analyses and the results of large
trials89; in extreme cases, large trials might indicate that the
combined results of smaller trials are incorrect in magnitude or
direction.90 When the results of large trials differ from the results
of small trials, commonly used methods for meta-analysis could
be inappropriate.91 All things being equal (such as risk of bias
and implementation), researchers and clinicians have been
advised to trust large simple trials rather than meta-analyses of
small trials.92 93
The deworming and vitamin (DEVTA) trial is the largest
randomised controlled trial ever conducted, including about a
million children in 72 clusters, more than four times the number
of children in this review. The trial registration describes a
factorial study comparing deworming and vitamin A, which
was delivered every six months for two years.79 The study began
in 1999 and recruitment closed in 2004. The authors were
contacted several times before our review was completed, but
they did not provide information about the conduct of the study.
We are unaware of any published results. We were therefore
unable to assess eligibility, potential risk of bias, implementation
of the intervention, or the generalisability of results. The authors
did provide an early analysis of the primary outcome (rate
ratio=0.96, 0.89 to 1.03), as well as analyses of cause specific
mortality and vitamin A serum concentration.

Details that might explain differences between DEVTA and our
review were not available, but we find it unlikely that the results
of our review can be explained by small study bias. Small studies
could differ from mega-trials, but five trials in this review
included more than 20 000 participants and nine included more
than 10 000 participants. Furthermore, when the mortality data
for DEVTA are included, results of the primary analysis remain
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

significant with a fixed effect model, and that effect remains
clinically meaningful.

Heterogeneity
Statistical heterogeneity suggests there might be differences in
the effects of vitamin A supplementation across settings and
populations, and we conducted prespecified subgroup analyses
for all analyses with 10 or more studies.

Trials were conducted in 18 countries. As described above,
vitamin A supplementation was associated with significant
reductions in mortality in both Asia and Africa. While the
difference between subgroups for the primary outcome was not
significant, biochemical concentrations of vitamin A seem lower
in Asia than in Africa,83 and our results are consistent with the
hypothesis that the benefits of supplementation in Asia might
be greater.94

For ethical reasons, some trials provided supplements to all
children with symptoms of vitamin A deficiency (such as Bitot’s
spots). Exclusion of such children limits the magnitude of effects
on vision outcomes, and such restrictions could contribute to
observed heterogeneity across other outcomes in this review.
Universal supplementation could result in larger benefits than
those reported here.

A non-representative subset of studies reported data by age and
sex, but these comparisons cannot be interpreted meaningfully
except insofar as vitamin A supplementation was associated
with significant reductions in mortality for all subgroups. All
studies reporting the primary outcome used the standard dose
recommended by WHO (table 2), except for one.52 While
differences between these subgroups were significant, the results
might be a statistical artefact; it is possible that small frequent
doses will lead to large reductions in mortality, but it seems
unlikely that a single supplement is more effective than multiple
supplements of the same dose.

Though we did not find evidence of specific contributors to
heterogeneity in this review, effects might differ according to
baseline vitamin A status, the availability of other nutrients, or
the prevalence of disease—for example, concomitant nutrient
deficiencies could impair the bioavailability of vitamin A
supplementation95 and differences in the prevalence of
pathogens, sanitation, immunisation, and access to healthcare
could affect the relative impact of vitamin A supplementation.
Heterogeneity might be related to differences in the
implementation of interventions, details of which are routinely
under-reported in trials.96 For example, it is essential that
providers distribute capsules effectively, that capsules have been
stored properly and remain active, and that children ingest the
supplements.
Subgroup analyses in this review were limited by the available
data, and meta-analyses of group level data to explore individual
level moderators should be interpreted with caution. Further
analyses with individual patient data from randomised controlled
trials and observational studies would be more informative.

Implications for policy
Vitamin A deficiency is a common condition that contributes
to illness, blindness, and death; supplements can reduce these
problems for children aged under 5 in low and middle income
countries. National and regional supplementation programmes
could be among the world’s most cost effective public health
interventions.97 If the risk of death for 190 million children
deficient in vitamin A were reduced by 24%, estimates from
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2008 suggest that over 600 000 lives could be saved each year98
and 20 million disability adjusted life years would be gained.99

Although vitamin A supplementation has been available in many
countries for over a decade, direct evidence for its contribution
to reducing child mortality is not available. Many countries
have experienced significant reductions in child mortality,5 100
and vitamin A supplementation programmes might have
contributed to these declines.

Supplementation responds to an immediate need, but, in the
long term, good nutrition requires reliable access to various
fresh foods. Fortification, food distribution programmes, and
horticultural developments might provide more permanent
solutions. For example, growers could increase access to
agricultural products like the orange fleshed sweet potato.101
Vitamin A could be added to rice, though fortification
programmes must minimise risk of toxicity. Until such long
term solutions are in place, supplementation should continue.
As access to vitamin A increases, it will be important to continue
to identify at risk groups and to deliver supplements to them.
Our review suggests potential pathways through which vitamin
A supplementation reduces mortality. Increased vaccination
against measles and other diseases will reduce the effect of
vitamin A supplementation if its primary effect is to prevent
infection; widespread supplementation, however, will remain
important because vitamin A affects other systems—for
example, supplementation can prevent blindness.

Based on these results, we strongly recommend vitamin A
supplementation for children aged under 5 in areas at risk of
vitamin A deficiency. Despite widespread efforts, vitamin A
programmes do not reach all children who could benefit.15
Universal distribution could be achieved in several ways.
Vitamin A supplementation can be provided when children
receive other services like vaccinations,102 and it can be provided
on a large scale. Child health days or other strategies might be
used to increase awareness,103 and vitamin A uptake could be
increased through national food programmes104 or through
delivery by community health workers.105

Implications for future research
The effectiveness of vitamin A supplementation is so well
established that further placebo controlled studies are not
required. Nevertheless, this review does not identify the most
effective dose or frequency of delivery. Large doses in the
included studies were effective. Smaller, more frequent doses
might produce larger reductions in mortality; more complex
and burdensome programmes, however, could result in lower
coverage. We suggest that policymakers consider including
trials of dose and frequency in vitamin A distribution
programmes. Other studies might investigate different delivery
channels, including food supplementation, horticultural
innovations, improved access to food, or psychosocial
programmes to increase uptake of foods rich in vitamin A.

Conclusions
Our review reaffirms compelling evidence that vitamin A
supplements can prevent death and illness in children aged 6
months to 5 years. Supplements are inexpensive and have few
side effects. Further trials are needed to determine the most
effective dose and frequency of supplementation, but placebo
controlled trials would be unethical. Policymakers should
continue working to provide supplements for all children at risk
of deficiency, particularly those in low and middle income
countries.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions

We are grateful to the Cochrane Collaboration for their assistance in
preparing this review. We particularly thank the Cochrane Developmental
Psychosocial and Learning Problems Group, including Jo Abbott, Chris
Champion, and Laura MacDonald. Margaret Anderson developed the
search strategy and Geraldine Macdonald edited the review. We thank
the Cochrane Editorial Unit, particularly Toby Lasserson, Rachel Murphy,
and Karla Soares-Weiser for extracting data; we thank David Tovey
and Harriet MacLehose for advice and for helping to manage the project.
We are grateful to Toby Lasserson for the table summarising of findings.
Henry Ebron from DistillerSR provided assistance managing the data.
We thank Julian Higgins and the Cochrane Methods Group for statistical
advice and assistance. Anonymous peer reviewers offered helpful
feedback on the protocol and the review, for which we are grateful.
Contributors: All authors contributed to the planning, conduct, and
reporting of this work, and to writing the abstract; specifically, the
background (AI, EM-W), methods (EM-W, AI, KH), literature search
(KH, AI, MYY), data extraction (EM-W, AI, KH, MYY), tables (AI, EM-W,
MYY), data analysis (EM-W, KH), results (EM-W, KH), discussion
(EM-W, AI, KH), and overall supervision (ZAB). In addition to the authors
Margaret Anderson developed the search strategy. Toby Lasserson,
Rachel Murphy, and Karla Soares-Weiser extracted data. Toby
Lasserson made the summary of findings table. Julian Higgins provided
statistical advice and calculated intracluster correlation coefficient values.
ZAB is guarantor.
Funding: The preparation of this review was funded by the Department
of Nutrition for Health and Development, WHO, Switzerland. EMW and
KH were supported by the University of Oxford’s department of social
policy and intervention and the centre for evidence-based intervention.
KH received funding from a Marshall scholarship. AI, MYY, and ZAB
were supported by Aga Khan University, Karachi, Pakistan.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: no support from
any organisation for the submitted work; no financial relationships with
any organisations that might have an interest in the submitted work in
the previous three years; no other relationships or activities that could
appear to have influenced the submitted work.
Ethical approval: Not required.
Data sharing: Detailed tables and effects for each study are available
from our Cochrane Review (www.cochrane.org).
1
2
3
4
5
6
7
8
9
10
11

12
13
14
15

Bates CJ. Vitamin A. Lancet 1995;345:31-5.
Green HN, Mellanby E. Vitamin A as an anti-infective agent. BMJ 1928;ii:691-6.
Sommer A, West KP. Vitamin A deficiency: health, survival, and vision. Oxford University
Press, 1996.
Rice AL, West KP Jr, Black RE. Vitamin A deficiency. Global and regional burden of
disease attributable to selected major risk factors. Vol 1. World Health Organization, 2004.
Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional,
and national causes of child mortality in 2008: a systematic analysis. Lancet
2010;375:1969-87.
Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, et al. Maternal and
child undernutrition: global and regional exposures and health consequences. Lancet
2008;371:243-60.
De Pee S, West CE, Muhilal M, Karyadi D, Hautvast JG. Lack of improvement in vitamin
A status with increased consumption of dark-green leafy vegetables. Lancet
1995;346:75-81.
Tang G. Bioconversion of dietary provitamin A carotenoids to vitamin A in humans. Am
J Clin Nutr 2010;91:1468-73S.
Smith FR, Goodman DS. Vitamin A transport in human vitamin A toxicity. N Engl J Med
1976;294:805-8.
Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresan PR, Wilkening VL.
Evaluation of vitamin A toxicity. Am J Clin Nutr 1990;52:183-202.
Beaton G, Martorell R, Aronson K, Edmonston B, McCabe G, Ross A, et al. Effectiveness
of Vitamin A supplementation in the control of young child morbidity and mortality in
developing countries. United Nations Administrative Committee on
Coordination/Sub-Committee on Nutrition,1993.
Fawzi WW, Chalmers TC, Herrera MG, Mosteller F. Vitamin A supplementation and child
mortality. A meta-analysis. JAMA 1993;269:898-903.
Glasziou PP, Mackerras DE. Vitamin A supplementation in infectious diseases: a
meta-analysis. BMJ 1993;306:366-70.
World Health Organization. Vitamin A supplements: a guide to their use in prevention and
treatment of vitamin A deficiency and xerophthalmia. WHO, 1997.
Bhutta ZA, Chopra M, Axelson H, Berman P, Boerma T, Bryce J, et al. Countdown to
2015 decade report (2000-10): taking stock of maternal, newborn, and child survival.
Lancet 2010;375:2032-44.

Subscribe: http://www.bmj.com/subscribe

BMJ 2011;343:d5094 doi: 10.1136/bmj.d5094

Page 8 of 19

RESEARCH

What is already known on this topic
Vitamin A is an essential nutrient; it must be obtained through diet
In low and middle income countries, many people (especially children) do not eat enough vitamin A
Vitamin A deficiency is related to vision problems and increased susceptibility to infectious disease and death
WHO recommends vitamin A supplements for children, pregnant women, and breastfeeding mothers
What this study adds
There have been 43 trials of vitamin A for children aged 6 months to 5 years old, including about 215 633 children
In low and middle income countries, vitamin A supplementation is associated with a 24% reduction in mortality
Vitamin A supplementation might reduce mortality by preventing measles and diarrhoea; it also prevents blindness
The evidence for vitamin A is compelling and clear; further trials comparing vitamin A with placebo would be unethical
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44
45

Kapil U. Time to stop giving indiscriminate massive doses of synthetic vitamin A to Indian
children. Public Health Nutr 2009;12:285-6.
Latham M. The great vitamin A fiasco. World Nutrition 2010;1:12-45.
Imdad AHK, Mayo-Wilson E, Yakoob MY, Bhutta ZA. Vitamin A supplementation for
preventing morbidity and mortality in children six months to five years of age. Cochrane
Database Syst -Rev 2010;5:CD008524 .
Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version
5.0.1. Cochrane Collaboration, 2008.
DistillerSR. Web-based systematic review software. 2011. http://systematic-review.net/.
Hedges LV. Distribution theory for Glass’s estimator of effect size and related estimators.
J Educ Stat 1981;6:107-28.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med
2002;21:1539-58.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
meta-analyses. BMJ 2003;327:557-60.
Duval SJ, Tweedie RL. Trim and fill: a simple funnel-plot based method of accounting for
publication bias in meta-analysis. Biometrics 2000;56:455-63.
Nordic Cochrane Centre. Review manager (RevMan). Version 5.0 [program]. Cochrane
Collaboration, 2008.
Biostat. Comprehensive meta-analysis. Version 2 [program]. Biostat, 2005.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of
evidence and strength of recommendations. BMJ 2004;328:1490.
Agarwal D, Pandey C, Agarwal K. Vitamin A administration and preschool child mortality.
Nutr Res 1995;15:669-80.
Arya S, Chellani H, Pandey J. Evaluation of safety of oral vitamin “A” megadose
co-administered with measles vaccination. Indian Pediatr 2000;37:1341-7.
Bahl R, Kumar R, Bhandari N, Kant S, Srivastava R, Bhan MK. Vitamin A administered
with measles vaccine to nine-month-old infants does not reduce vaccine immunogenicity.
J Nutr 1999;129:1569-73.
Barreto ML, Santos LM, Assis AM, Araujo MP, Farenzena GG, Santos PA, et al. Effect
of vitamin A supplementation on diarrhoea and acute lower-respiratory-tract infections in
young children in Brazil. Lancet 1994;344:228-31.
Benn CS, Aaby P, Bale C, Olsen J, Michaelsen KF, George E, et al. Randomised trial of
effect of vitamin A supplementation on antibody response to measles vaccine in
Guinea-Bissau, West Africa. Lancet 1997;350:101-5.
Biswas R, Biswas AB, Manna B, Bhattacharya SK, Dey R, Sarkar S. Effect of vitamin A
supplementation on diarrhoea and acute respiratory tract infection in children. A double
blind placebo controlled trial in a Calcutta slum community. Eur J Epidemiol 1994;10:57-61.
Cheng L, Chang Y, Wang EL, Brun T, Geissler C. Impact of large-dose vitamin A
supplementation on childhood diarrhoea, respiratory disease and growth. Eur J Clin Nutr
1993;47:88-96.
Cherian T, Sneha V, Raghupathy P, Ratnam S, Chandra RK. Effect of Vitamin A
supplementation on the immune response to measles vaccination. Vaccine
2003;21:2418-20.
Chowdhury S, Kumar R, Ganguly NK, Kumar L, Walia BN. Effect of vitamin A
supplementation on childhood morbidity and mortality. Indian J Med Sci 2002;56:259-64.
Daulaire NM, Starbuck ES, Houston RM, Church MS, Stukel TA, Pandey MR. Childhood
mortality after a high dose of vitamin A in a high risk population. BMJ 1992;304:207-10.
Dibley MJ, Sadjimin T, Kjolhede CL, Moulton LH. Vitamin A supplementation fails to
reduce incidence of acute respiratory illness and diarrhea in preschool-age Indonesian
children. J Nutr 1996;126:434-42.
Donnen P, Brasseur D, Dramaix M, Vertongen F, Zihindula M, Muhamiriza M, et al. Vitamin
A supplementation but not deworming improves growth of malnourished preschool children
in eastern Zaire. J Nutr 1998;128:1320-7.
Florentino RF, Tanchoco CC, Ramos AC, Mendoza TS, Natividad EP, Tangco JB, et al.
Tolerance of preschoolers to two dosage strengths of vitamin A preparation. Am J Clin
Nutr 1990;52:694-700.
Herrera MG, Nestel P, el Amin A, Fawzi WW, Mohamed KA, Weld L. Vitamin A
supplementation and child survival. Lancet 1992;340:267-71.
Kartasasmita CB, Rosmayudi O, Deville W, Demedts M. Plasma retinol level, vitamin A
supplementation and acute respiratory infections in children of 1-5 years old in a developing
country. Tuber Lung Dis 1995;76:563-9.
Lima AA, Soares AM, Lima NL, Mota RM, Maciel BL, Kvalsund MP, et al. Effects of vitamin
A supplementation on intestinal barrier function, growth, total parasitic, and specific Giardia
spp infections in Brazilian children: a prospective randomized, double-blind,
placebo-controlled trial. J Pediatr Gastroenterol Nutr 2010;50:309-15.
Lin J, Lai X, Qin J, Song F, Zhang Y, Yao P, et al. Effect of beta-carotene supplementation
on health and growth of vitamin A deficient children in China rural villages: a randomized
controlled trial. e-SPEN 2009;4:e17-21.
Lin J, Song F, Yao P, Yang X, Li N, Sun S, et al. Effect of vitamin A supplementation on
immune function of well-nourished children suffering from vitamin A deficiency in China.
Eur J Clin Nutr 2008;62:1412-8.

No commercial reuse: See rights and reprints http://www.bmj.com/permissions

46

47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72

Long KZ, Montoya Y, Hertzmark E, Santos JI, Rosado JL. A double-blind, randomized,
clinical trial of the effect of vitamin A and zinc supplementation on diarrheal disease and
respiratory tract infections in children in Mexico City, Mexico. Am J Clin Nutr
2006;83:693-700.
Long KZ, Rosado JL, DuPont HL, Hertzmark E, Santos JI. Supplementation with vitamin
A reduces watery diarrhoea and respiratory infections in Mexican children. Br J Nutr
2007;97:337-43.
Pant CR, Pokharel GP, Curtale F, Pokhrel RP, Grosse RN, Lepkowski J, et al. Impact of
nutrition education and mega-dose vitamin A supplementation on the health of children
in Nepal. Bull World Health Org 1996;74:533-45.
Pinnock CB, Douglas RM, Badcock NR. Vitamin A status in children who are prone to
respiratory tract infections. Aust Paediatr J 1986;22:95-9.
Pinnock CB, Douglas RM, Martin AJ, Badcock NR. Vitamin A status of children with a
history of respiratory syncytial virus infection in infancy. Aust Paediatr J 1988;24:286-9.
Rahman MM, Vermund SH, Wahed MA, Fuchs GJ, Baqui AH, Alvarez JO. Simultaneous
zinc and vitamin A supplementation in Bangladeshi children: randomised double blind
controlled trial. BMJ 2001;323:314-8.
Rahmathullah L, Underwood BA, Thulasiraj RD, Milton RC, Ramaswamy K, Rahmathullah
R, et al. Reduced mortality among children in southern India receiving a small weekly
dose of vitamin A. N Engl J Med 1990;323:929-35.
Ramakrishnan U, Latham MC, Abel R. Vitamin A supplementation does not improve
growth of preschool children: a randomized, double-blind field trial in south India. J Nutr
1995;125:202-11.
Ranjini EK, Cherian T, Balasubramaniam KA, Raghupathy P. Vitamin A supplementation
in children with recurrent respiratory infections. Indian Pediatr 2001;38:771-4.
Reddy V, Vijayaraghavan K, Mathur KK. Effect of deworming and vitamin A administration
on serum vitamin A levels in preschool children. J Trop Pediatr 1986;32:196-9.
Ross DA, Binka FN, Dollimore N, Smith PG, Addy HA, Tomkins AM, et al. Vitamin A
supplementation in northern Ghana: effects on clinic attendances, hospital admissions,
and child mortality. Lancet 1993;342:7-12.
Semba RD, Muhilal M, Scott AL, Natadisastra G, Wirasasmita S, Mele L, et al. Depressed
immune response to tetanus in children with vitamin A deficiency. J Nutr 1992;122:101-7.
Semba RD, Munasir Z, Beeler J, Akib A, Muhilal M, Audet S, et al. Reduced seroconversion
to measles in infants given vitamin A with measles vaccination. Lancet 1995;345:1330-2.
Sempertegui F, Estrella B, Camaniero V, Betancourt V, Izurieta R, Ortiz W, et al. The
beneficial effects of weekly low-dose vitamin A supplementation on acute lower respiratory
infections and diarrhea in Ecuadorian children. Pediatrics 1999;104:e1.
Shankar AH, Genton B, Semba RD, Baisor M, Paino J, Tamja S, et al. Effect of vitamin
A supplementation on morbidity due to Plasmodium falciparum in young children in Papua
New Guinea: a randomised trial. Lancet 1999;354:203-9.
Sinha DP, Bang FB. The effect of massive doses of vitamin A on the signs of vitamin A
deficiency in preschool children. Am J Clin Nutr 1976;29:110-5.
Smith JC, Makdani D, Hegar A, Rao D, Douglass LW. Vitamin A and zinc supplementation
of preschool children. J Am Coll Nutr 1999;18:213-22.
Sommer A, Tarwotjo I, Djunaedi E, West KP Jr, Loeden AA, Tilden R, et al. Impact of
vitamin A supplementation on childhood mortality. A randomised controlled community
trial. Lancet 1986;1:1169.
Stabell C, Bale C, Pedro da Silva A, Olsen J, Aaby P. No evidence of fontanelle-bulging
episodes after vitamin A supplementation of 6- and 9-month-old infants in Guinea Bissau.
Eur J Clin Nutr 1995;49:73-4.
Stansfield SK, Muller PL, Lerebours G, Augustin A. Vitamin A supplementation and
increased prevalence of childhood diarrhoea and acute respiratory infections. Lancet
1993;342:578-82.
Van Agtmaal EJ, Bloem MW, Speek AJ, Saowakontha S, Schreurs HP, van Haeringen
NJ. The effect of vitamin A supplementation on tear fluid retinol levels of marginally
nourished preschool children. Curr Eye Res 1988;7:43-8.
Venkatarao T, Ramakrishnan R, Nair NG, Radhakrishnan S, Sundaramoorthy L, Koya
PK, et al. Effect of vitamin A supplementation to mother and infant on morbidity in infancy.
Indian Pediatr 1996;33:279-86.
Vijayaraghavan K, Radhaiah G, Surya Prakasam B, Sarma KVR, Reddy V. Effect of
massive dose vitamin A on morbidity and mortality in Indian children. Lancet
1990;336:1342-5.
West KP Jr, Pokhrel RP, Katz J, LeClerq SC, Khatry SK, Shrestha SR, et al. Efficacy of
vitamin A in reducing preschool child mortality in Nepal. Lancet 1991;338:67-71.
Bhaskaram P, Rao KV. Enhancement in seroconversion to measles vaccine with
simultaneous administration of vitamin A in 9-months-old Indian infants. Indian J Pediatr
1997;64:503-9.
Bloem MW, van Agtmaal EJ, Speek AJ, Saowakontha S, Schreurs WHP. Vitamin A
intervention: short-term effects of a single, oral, massive dose on iron metabolism. Am J
Clin Nutr 1990;51:76-9.
Kothari G. The effect of vitamin A prophylaxis on morbidity and mortality among children
in urban slums in Bombay. J Trop Pediatr 1991;37:141.

Subscribe: http://www.bmj.com/subscribe

BMJ 2011;343:d5094 doi: 10.1136/bmj.d5094

Page 9 of 19

RESEARCH

73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91

Wu Z, Ouyang L. Impact of vitamin A on the immune function of infants. China Trop Med
2007;7:540-1.
Bahl R, Taneja S, Bhan MK. The impact of vitamin A supplementation on physical growth
of children is dependent on season. Eur J Clin Nutr 1997;51:26-9.
Semba RD, Natadisastra G, Muhilal M, Sommer A. Response of Bitot’s spots in preschool
children to vitamin A treatment. Am J Ophthalmol 1990;110:416-20.
Semba RD, Ndugwa C, Perry RT, Clark TD, Jackson JB, Melikian G, et al. Effect of
periodic vitamin A supplementation on mortality and morbidity of human immunodeficiency
virus-infected children in Uganda: a controlled clinical trial. Nutrition 2005;21:25-31.
Yang HM, Mao M, Wan CM. Vitamin A for treating measles in children. Cochrane Database
Syst Rev 2005;4:CD001479.
Aklamati E, Brown KH, Mulenga M, Kafwembe E, Peerson JM, Stephensen C, et al.
Impact of high-dose vitamin A supplements on vitamin A status of 3-4 y old Zambian boys.
Faseb J 2006;20:A1050.
DEVTA: cluster-randomised trial in 1 million children in North India. ILSI Micronutrient
Forum, 2007.
Ramakrishnan U, Darnton-Hill I. Assessment and control of vitamin A deficiency disorders.
J Nutr 2002;132:2947-53S.
Bhutta ZA. Effect of infections and environmental factors on growth and nutritional status
in developing countries. J Pediatr Gastroenterol Nutr 2006;43:S13-21.
Demissie T, Ali A, Mekonnen Y, Haider J, Umeta M. Demographic and health-related risk
factors of subclinical vitamin A deficiency in Ethiopia. J Health Popul Nutr 2009;27:666-73.
WHO. Global prevalence of vitamin A deficiency in populations at risk 1995-2005. WHO
global database on vitamin A deficiency. World Health Organization, 2009.
Imdad A, Haider BA, Bhutta ZA. Nutrition interventions for maternal and child health and
survival.Vol 1. Oxford University Press, 2010.
Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic review
of the empirical evidence of study publication bias and outcome reporting bias. PLoS One
2008;3:e3081.
Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of
outcome reporting bias in randomised controlled trials on a cohort of systematic reviews.
BMJ 2010;340:c365.
Mayo-Wilson E, Montgomery P. Missing data in systematic reviews: a table might help
(poster). Joint Colloquium of the Cochrane and Campbell Collaborations, 2010.
Gogia S, Sachdev H. Vitamin A supplementation for the prevention of morbidity and
mortality in infants six months of age or less (review). Cochrane Database Syst Rev
2008;4:CD007480.
LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between
meta-analyses and subsequent large randomized, controlled trials. N Engl J Med
1997;337:536-42.
Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and
overviews of trials. J Clin Epidemiol 1995;48:23-40.
Higgins JP, Spiegelhalter DJ. Being sceptical about meta-analyses: a Bayesian perspective
on magnesium trials in myocardial infarction. Int J Epidemiol 2002;31:96-104.

No commercial reuse: See rights and reprints http://www.bmj.com/permissions

92
93
94
95
96
97
98
99
100
101
102
103
104
105

Bailar JC 3rd. The promise and problems of meta-analysis. N Engl J Med 1997;337:559-61.
Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate
benefits. BMJ 1998;317:1170-1.
Imdad A, Yakoob MY, Sudfeld C, Haider BA, Black RE, Bhutta ZA. Impact of vitamin A
supplementation on infant and childhood mortality. BMC Public Health 2011;11:S20.
Villamor E, Fawzi WW. Vitamin A supplementation: implications for morbidity and mortality
in children. J Infect Dis 2000;182:S122-33.
Mayo-Wilson E. Reporting implementation in randomized trials: proposed additions to the
consolidated standards of reporting trials statement. Am J Public Health 2007;97:630-3.
Fawzi WW. The benefits and concerns related to vitamin A supplementation. J Infect Dis
2006;193:756-9.
Bhutta ZA, Ahmed T, Black RE, Cousens S, Dewey K, Giugliani E, et al. What works?
Interventions for maternal and child undernutrition and survival. Lancet 2008;371:417-40.
World Health Organization. Global health risks: mortality and burden of disease attributable
to selected major risks. WHO, 2009.
You D, Wardlaw T, Salama P, Jones G. Levels and trends in under-5 mortality, 1990-2008.
Lancet 2010;375:100-3.
Klemm RD, West KP Jr, Palmer AC, Johnson Q. Randall P, Ranum P, et al. Vitamin A
fortification of wheat flour: considerations and current recommendations. Food Nutr Bull
2010;31: S47-61.
Wallace A, Dietz V, Cairns KL. Integration of immunization services with other health
interventions in the developing world: what works and why? Systematic literature review.
Trop Med Int Health 2009;14:11-9.
Oliphant NP, Mason JB, Doherty T, Chopra M, Mann P, Tomlinson M, et al. The
contribution of child health days to improving coverage of periodic interventions in six
African countries. Food Nutr Bull 2010;31:S248-63.
Semba RD, de Pee S, Sun K, Bloem MW, Raju VK. The role of expanded coverage of
the national vitamin A program in preventing morbidity and mortality among preschool
children in India. J Nutr 2009;140:208-12S.
Lassi ZS, Haider BA, Bhutta ZA. Community-based intervention packages for reducing
maternal and neonatal morbidity and mortality and improving neonatal outcomes. Cochrane
Database Syst Rev 2010;11:CD007754.

Accepted: 07 July 2011
Cite this as: BMJ 2011;343:d5094
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/bync/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

Subscribe: http://www.bmj.com/subscribe

BMJ 2011;343:d5094 doi: 10.1136/bmj.d5094

Page 10 of 19

RESEARCH

Tables
Table 1| Characteristics of included studies in review of effect of vitamin A supplementation on mortality, illness, and blindness in children

aged under 5

Country

Age (months)

No of
participants

Follow-up
(months)

Dose (1000 IU)

Frequency*

Agarwal 199528

India

0-72

17 778†

15, 27

50 at 1-6 m; 100 at >6 m

0, 4, 8, 12 m

Arya 200029

India

9-12

256

24 hour

100

1 dose

Bahl 199930

India

6-9

618

4

100

1 dose

Barreto 1994

Brazil

6-48

1240

12

100 at <12 m; 200 ≥12 m

0, 4, 8, 12 m

Benn 199732

Guinea Bissau

6-9

462

12

100

1 dose

Biswas 199433

India

12-71

180

6

200

1 dose

Cheng 1993

China

6-36

198

12

100 at <12 m; 200 ≥12 m

4, 10 m

Cherian 200335

India

6-9

395

6

100

1 dose

Chowdhury 2002β 36

India

<120

1520

15

50 at <6 m; 100 at 6-12 m;
200 at >12m

0, 5, 10 m

Daulaire 1992‡37

Nepal

1-59

7197†

5

50 at <6 m; 100 at 6-12 m;
200 at ≥12 m

1 dose

Indonesia

6-47

1405

24

103 at <12 m; 206 at ≥12 m 0, 4, 8, 12, 16, 20, 24 m

Study

31

34

Dibley 199638
Donnen 1998‡

39

Florentino 199040
Herrera 199241
Kartasamita 199542

Congo (Zaire)

0-72

235

12

100 at <12 m; 200 at ≥12 m

Philippines

12-72

2471

1 week

100, 200§

0, 6, 12 m
1 dose

Sudan

9-72

28 753

18

200

0, 6, 12, 18 m
0, 6, 12 m

Indonesia

12-54

267

12

200

Lima 2010‡ 43

Brazil

2-108

79

36

100 at <12 m; 200 at ≥12 m

0, 4, 8m

Lin 200845

China

24-84

70

3

100

0, 0.5, 1, 1.5, 2, 2,5, 3 m

Lin 200944

China

6-84

86

3

100

0, 1, 2, 3 m

Long 200646

Mexico

6-15

786

12

20 at <12 m; 45 at ≥12 m

0, 2, 4, 6, 8, 10, 12 m

Long 200747

Mexico

6-15

195

12

20 at <12 m; 45 at ≥12 m

0, 2, 4, 6, 8, 10, 12 m

Pant 1996‡

Nepal

6-120

25 301†

24

100 at 6-12 m; 200 at ≥12 m

1 dose

Pinnock 198649

Australia

1-48

147

20 weeks

3.9

3/week for 20 weeks

Pinnock 198850

Australia

0-24

206

12

14

Weekly for 1 year

Rahman 2001

48

Bangladesh

12-35

800

6

200

1 dose

Rahmathullah 199052

India

6-60

15 419†

12

8.333

Weekly for 1 year

Ramakrishnan 199553

India

6-36

583

12

100 at <12 m; 200 at ≥12 m

0, 4, 8, 12 m

Ranjini 200154

India

12-60

61

6

200

1 dose

Reddy 1986

51

India

12-60

487

12

200

1 dose

Ross 1993 health56

Ghana

6-59

1455

12

100 at 6-12 m; 200 at ≥12 m

0, 4, 8, 12 m

Ross 1993 survival56

100 at 6-12 m; 200 at ≥12 m 0, 4, 8, 12, 16, 20, 24 m

55

Ghana

6-90

21 906†

12

Semba 1992

57

Indonesia

36-72

236

1

200

Semba 199558

Indonesia

6

336

6

100

1 dose

Ecuador

6-36

400

9

10

Weekly for 40 w
0, 4, 8, 12 m

Sempertegui 199959
Shankar 199960

1 dose

Papa New Guinea

6-60

480

13

100 at <12 m; 200 at ≥12 m

Sinha 197661

India

2-54

306

12

200

0, 4, 8, 12 m

Smith 199962

Belize

26-66

51

6

10

Weekly for 26 w
0, 6 m

Sommer 1986‡ 63
Stabell 199564
Stansfield 199365
van Agtmaal 198866‡

Indonesia

0-71

29 236†

9-13

200

Guinea Bissau

6

68

30

100

0, 3 m

Haiti

6-83

13 651

12

100 at 6-11 m; 200 at ≥12 m

0, 4, 8 m
1 dose

Thailand

37

30

4

200

Venkatarao 199667

India

6

612

6

200

1 dose

Vijyagharvan 199068

India

12-60

15 775†

12

200

0, 6, 12 m

West 199169

Nepal

6-72

28 630†

16

100 at 6-11 m; 200 at ≥12 m

0, 4, 8, 12 m
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Table 1 (continued)
Study

Country

Age (months)

No of
participants

Follow-up
(months)

Dose (1000 IU)

Frequency*

*Several studies did not explicitly state number of doses received. We assumed that children received doses at baseline and end point—for example, “every 4
months for 1 year” appears as 0, 4, 8, and 12 months.
†Cluster randomised.
‡Compared vitamin A with treatment as usual (control group did not receive placebo).
§Two eligible intervention groups combined for analysis.
¶Mean.
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Table 2| Subgroup analyses for all cause mortality at longest follow-up in studies of effect of vitamin A supplementation in children aged

under 5

No (%) in primary analysis
Subgroup (test for difference)

All trials

Trials

Participants

Fixed effect rate ratio (95% CI)

Heterogeneity: I2 (%); Q

43

16 (37)

194 483 (90)

0.76 (0.69 to 0.83)

48%; 29.10 (P=0.02)

All

—

16 (37)

194 483 (90)

—

—

Africa33 39 41 56 64

6

5 (12)

52 811 (25)

0.85 (0.73 to 0.98)

59%; 9.81 (P=0.04)

Australia49 50

2

0

0

—

—

Asia

28

10 (23)

140 432 (65)

0.69 (0.61 to 0.79)

40%; 15.00 (P=0.09)

7

1 (2)

1240 (<1)

1.00 (0.14 to 7.08)

—

All

—

16 (37)

194 483 (90)

—

—

(Peri)urban 29 30 32 33 35 36 42 43 45-47 49-51 54 59

16

2 (5)

1982 (<1)

NA

NA

Rural28 31 34 37-41 44 48 52 53 55-58 60-69

27

14 (33)

192 501 (89)

NA

NA

All

—

16 (37 )

194 483 (90)

0.76 (0.69 to 0.83)

48%; 29.10 (P=0.02)

WHO (single)29 30 32 33 36 37 40 48 51 54 55 57 58 66 67

15

4 (9)

33 572 (16)

0.66 (0.52 to 0.83)

0%; 2.15 (P=0.54)

WHO (4-6m)

18

11 (26)

147 933 (69)

0.81 (0.72 to 0.90)

48%; 19.17 (P=0.04)

10

1 (2 )

15 419 (7)

0.46 (0.30 to 0.71)

—

—

5 (12)

61 544 (29)

0.66 (0.56 to 0.77)

0.0%; 6.77 (P=0.45)

6-12 months

32

4 (9)

4739 (2)

0.59 (0.43 to 0.82)

15%; 3.51 (P=0.32)

12-60 months28 31 33 34 36-57 59-66 68 69

37

4 (9)

56 805 (26)

0.68 (0.57 to 0.81)

0.0%; 2.72 (P=0.44)

All

—

5 (12)

85 568 (40)

0.80 (0.70 to 0.91)

34%; 10.69 (P=0.15)

Males28-69

43

5 (12)

43 567 (20)

0.80 (0.66 to 0.97)

62%; 7.79 (P=0.05)

Females

43

5 (12)

42 001 (20)

0.79 (0.65 to 0.95)

0.0%; 2.87 (P=0.41)

44

17 (39)

1 194 483 (98)

0.88 (0.84 to 0.94)

64%; 44.31 (P<0.001)

All studies

28-69

Location (P=0.12):

28-30 33-38 40 42 44 45 48 51-55 57 58 60 61 63 66-69

Latin America31 43 46 47 59 62 65
Setting (NA):

Dose (P=0.02):

28 31 34 36 38 39 41-47 53 56 60 61 63-65 68 69

More frequent44-47 49 50 52 59 62 64
Age* (P=0.46):
All
28-32 34-39 41 44 44 46-50 52 53 56 58-61 64-65

67 69

Sex† (P=0.89):

28-69

With DEVTA28-69 79

NA=not available; planned analysis not conducted; DEVTA=deworming and vitamin A trial.
33

64

*For primary outcome, trials reported mortality for children <12 months, children >12 months, or both.
46

†One trial reporting data by sex reported no events, and four trials appear in both analysis.
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Table 3| Summary of pooled analyses for mortality and illness in studies of effect of vitamin A supplementation in children aged under 5
No (%) of trials
(n=43)

Outcome

No (%) of participants Rate ratio (95% CI), fixed
(n=215 633)
effect
Heterogeneity: I2; χ²

Follow-up
(weeks)

Quality of evidence
(GRADE)

Primary outcome
All cause mortality31 32 36-39

16 (37)

194 483 (90)

0.76 (0.69 to 0.83)

48%; 29.10 (P=0.02)

12-96

High

Diarrhoea28 36 37 41 52 56 67

7 (16)

90 951 (42)

0.72 (0.57 to 0.91)

2%; 6.12 (P=0.41)

48-104

Moderate

Measles28 37 41 52 56

5 (12)

88 261 (41)

0.80 (0.51 to 1.24)

0%; 0.40 (P=0.98)

52-104

Moderate

Meningitis28 36 56

3 (7)

41 204 (19)

0.57 (0.17 to 1.88)

0%; 0.75 (P=0.69)

48-108

Low

LRTI28 36 37 41 52 56 67

7 (16)

90 951 (42)

0.78 (0.54 to 1.14)

14%; 7.00 (P=0.32)

48-104

Low

13 (30)

37 710(17)

0.85 (0.82 to 0.87)

95%; 217.99 (P<0.01)

24-60

Low

2 (5)

14 437 (7)

1.08 (1.05 to 1.12)

87%; 15.76 (P<0.01)

48

Very low

41 45 48 52 56 63 68 69 107

Cause specific mortality

Illness
Diarrhoea:
Incidence29 31 33 34 36 38 40 41

47 53 59 60 67

Prevalence35 47 65
Malaria:
Incidence60

1 (2)

480 (<1)

0.73 (0.60 to 0.88)

NA

52

Very low

Prevalence56

2 (5)

23 361 (11)

0.72 (0.41 to 1.28)

0%; 0.02 (P=0.88)

48

Moderate

Incidence30-32 36 41 58

6 (14)

19 566 (9)

0.50 (0.37 to 0.67)

0%; 0.55 (0.99);

16-78

High

Prevalence

0 (0)

0 (0)

NA

NA

NA

NA

Incidence31 34 36 42 47 59 67

7 (16)

18 179 (8)

1.14 (0.95 to 1.37)

22%; 7.66 (0.26)

24-60

Very low

Prevalence

1 (2)

786 (0.4)

0.46 (0.21 to 1.03)

NA

48

Very low

Measles:

LRTI:
46

LRTI=lower respiratory tract infection.
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Table 4| Summary of pooled analyses for admission to hospital, vision, vitamin A deficiency, and adverse events in studies of effect of

vitamin A supplementation in children aged under 5

No (%) of trials No (%) of participants Rate ratio (95% CI), fixed
(n=43)
(n=215 633)
effect

Outcome

Heterogeneity: I2; χ²

Follow-up
(weeks)

Quality of evidence
(GRADE)

Admission to hospital
All cause56

1 (2)

1185 (0.5)

0.64 (0.40 to 1.02)

NA

48

Very low

Diarrhoea

1 (2)

198 (<1)

0.25 (0.01 to 6.11)

NA

48

Very low

1 (2)

198 (<1)

0.11 (0.01 to 2.06)

NA

48

Very low

Incidence41

1 (2)

28 753 (13)

0.93 (0.76 to 1.14)

NA

72

Very low

Prevalence48 61 63 69

4 (9)

63 278 (29)

0.45 (0.33 to 0.61)

64%; 8.25 (P=0.04)

36-96

Moderate

Incidence41

1 (2)

28 753 (13)

0.53 (0.28 to 0.99)

NA

72

Low

Prevalence63 69

2 (5)

22 972 (11)

0.32 (0.21 to 0.50)

0%; 0.19 (P=0.66)

52-68

Moderate

Incidence31 41 69

3 (7)

58 623 (27)

0.85 (0.70 to 1.03)

63%; 2.69 (P=0.10)

48-72

Low

Prevalence31 63 69

2 (5)

57 866 (27)

0.31 (0.22 to 0.45)

0%; 0.22 (P=0.64)

36-64

Moderate

4 (9)

2262 (1)

0.71 (0.65 to 0.78)

78%; 13.58 (P<0.01)

24-96

High

13 (30)

6623 (3)

g=0.31 (0.26 to 0.36)

95%; 270.23 (P<0.01)

4-96

Moderate

34

LRTI34
Vision
Bitot’s spots:

Night blindness:

Xerophthalmia:

Vitamin A deficiency
Number deficient38 54 56 60
Serum concentration34 38 42
44 49 50 54-57 59 60

Adverse events
Vomiting29 40 61

3 (7)

2994 (1)

2.75 (1.81 to 4.19)

21%; 2.53 (P=0.28)

48 hours

Very low

Bulging fontanelle29 30 64

3 (7)

885 (<1)

5.00 (0.24 to 103.72)

NA

48 hours

Low

NA=not available; LRTI=lower respiratory tract infection.
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Figures

Fig 1 Identification of studies to include in review of effect of vitamin A supplementation on mortality, illness, and blindness
in children aged under 5
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Fig 2 Assessment of risk of bias in studies on effect of vitamin A supplementation on mortality, illness, and blindness in
children aged under 5
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Fig 3 All cause mortality in studies on effect of vitamin A supplementation in children aged under 5

Fig 4 All cause mortality sensitivity analysis in studies on effect of vitamin A supplementation in children aged under 5,
including deworming and vitamin A (DEVTA) trial
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Fig 5 All cause mortality by dose in studies on effect of vitamin A supplementation in children aged under 5

Fig 6 Mortality funnel plot with trim and fill in studies on effect of vitamin A supplementation in children aged under 5.
Observed=included studies. Imputed=observed effects trimmed to make funnel plot symmetrical, opposite effects imputed,
trimmed studies and imputed effects replaced
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Fig 7 Incidence of diarrhoea in studies on effect of vitamin A supplementation in children aged under 5

Fig 8 Incidence of measles in studies on effect of vitamin A supplementation in children aged under 5

Fig 9 All cause mortality cumulative meta-analysis in studies on effect of vitamin A supplementation in children aged under
5

No commercial reuse: See rights and reprints http://www.bmj.com/permissions

Subscribe: http://www.bmj.com/subscribe

